Thursday, February 23, 2012

Qnexa fda

  • SILVER SPRING, Md. -- A previously rejected weight loss pill won an overwhelming endorsement from public health advisers Wednesday, raising hopes that the drug from Vivus Inc. could become the first new anti-obesity medication to reach the U.
  • (Huffington Post)
  • Vivus has spent thirteen years developing and testing Qnexa and was rebuffed two years ago when the same FDA advisory panel rejected the drug over safety concerns.
  • (PR Newswire)
  • On Early Start, Dr. Louis Aronne, Director of the Comprehensive Weight Control Program at New York Presbyterian Weill Cornell Medical Center, discusses the risks and benefits of the new diet pill Qnexa, which will likely receive FDA approval.
  • (CNN)
  • A panel of medical experts voted overwhelmingly Wednesday to endorse the controversial weight-loss drug Qnexa, clearing the way for the Food and Drug Administration to approve a new prescription obesity medication for the first time since 1999.
  • (Los Angeles Times)
  • Shares of NeuroSearch A/S and Novo Nordisk A/S, Danish companies developing obesity treatments, also gained after advisers to the Food and Drug Administration voted 20-2 yesterday that Qnexa's benefits outweigh its risks.
  • (Businessweek)
  • A previously rejected weight loss pill won an overwhelming endorsement from public health advisers Wednesday, raising hopes that the drug from Vivus Inc. could become the first new anti-obesity medication to reach the U.S.
  • (Time)
  • Feb. 22 (Bloomberg) -- Vivus Inc.s weight-loss pill Qnexa won the backing of a U.S. advisory panel as the company seeks to gain approval for the first new obesity drug in 13 years. The shares doubled in late trading.
  • (BusinessWeek)
  • Qnexa, which is made by a small California firm called Vivus Inc., and two other weight-loss drugs were rejected by the FDA in the past two years on concerns about potential safety risks.
  • (Wall Street Journal)
  • MOUNTAIN VIEW, Calif., Feb. 22, 2012 /PRNewswire/ -- VIVUS, Inc. (NASDAQ: VVUS - News) today announced that the U.S.
  • (Yahoo Finance)
  • For 10 years, Louis Aronne has been giving patients a combination of phentermine, a 50-year-old stimulant widely used to control appetite, and topiramate, a newer antiseizure drug, to help them lose weight.
  • (Philadelphia Daily News)

No comments:

Post a Comment

Post a Comment